Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06741358 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Using Glialia for Treating Persistent Perceptual Postural Dizziness

Study acronym: GLI-PPPD
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Oct 10, 2026 to May 10, 2027
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 6 of 6 entries
    • Publications: details revised at 4 of 4 entries
  2. Start date: Oct 11, 2024 to Dec 21, 2024
    • Site contact updated
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This pilot study will involve 30 participants recruited from the Santa Lucia Foundation IRCCS, including 20 patients diagnosed with Persistent Perceptual Postural Dizziness (PPPD), and might or might not have previously contracted Sars Cov2 infection. They who will be randomly assigned to receive either the Glialia supplement or placebo. Additionally, 10 control participants who have recovered from COVID-19 will receive Glialia to help assess the influence of previous COVID-19 infection on neuroinflammation levels. The study aims to compare baseline neuroinflammation levels between PPPD patients and controls, measure changes in neuroinflammation in all groups after treatment and to determine if the reduction in neuroinflammation is more significant in the Glialia group compared to the placebo group. The trial will be conducted in a triple-blind manner, ensuring that neither participants nor researchers know the treatment assignments. Each participant will receive sachets to be taken daily for 60 days, with the study providing both the Glialia supplement and placebo at no cost.
Trial Details
NCT Number NCT06741358
Lead Sponsor I.R.C.C.S. Fondazione Santa Lucia
Conditions
(from sponsor)		 Persistent Postural Perceptual Dizziness
Related terms Neuroinflammatory Diseases
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov